Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine] (MDA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00823407

Recruitment Status : Completed

First Posted : January 15, 2009

Last Update Posted : May 31, 2013

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

National Institute on Drug Abuse (NIDA)

University of California, San Francisco

Information provided by (Responsible Party):

John Mendelson, MD, California Pacific Medical Center Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	July 2009
Actual Study Completion Date :	July 2009

Publications of Results:

Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE. Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One. 2010 Dec 2;5(12):e14074. doi: 10.1371/journal.pone.0014074.

To Top